157 related articles for article (PubMed ID: 21372048)
1. InACTIVatINg cancer cachexia.
Mathew SJ
Dis Model Mech; 2011 May; 4(3):283-5. PubMed ID: 21372048
[TBL] [Abstract][Full Text] [Related]
2. Elevated expression of activins promotes muscle wasting and cachexia.
Chen JL; Walton KL; Winbanks CE; Murphy KT; Thomson RE; Makanji Y; Qian H; Lynch GS; Harrison CA; Gregorevic P
FASEB J; 2014 Apr; 28(4):1711-23. PubMed ID: 24378873
[TBL] [Abstract][Full Text] [Related]
3. The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy.
Zhong X; Pons M; Poirier C; Jiang Y; Liu J; Sandusky GE; Shahda S; Nakeeb A; Schmidt CM; House MG; Ceppa EP; Zyromski NJ; Liu Y; Jiang G; Couch ME; Koniaris LG; Zimmers TA
J Cachexia Sarcopenia Muscle; 2019 Oct; 10(5):1083-1101. PubMed ID: 31286691
[TBL] [Abstract][Full Text] [Related]
4. Myostatin is a novel tumoral factor that induces cancer cachexia.
Lokireddy S; Wijesoma IW; Bonala S; Wei M; Sze SK; McFarlane C; Kambadur R; Sharma M
Biochem J; 2012 Aug; 446(1):23-36. PubMed ID: 22621320
[TBL] [Abstract][Full Text] [Related]
5. A TGF-β pathway associated with cancer cachexia.
Guttridge DC
Nat Med; 2015 Nov; 21(11):1248-9. PubMed ID: 26540384
[TBL] [Abstract][Full Text] [Related]
6. Pro-cachectic factors link experimental and human chronic kidney disease to skeletal muscle wasting programs.
Solagna F; Tezze C; Lindenmeyer MT; Lu S; Wu G; Liu S; Zhao Y; Mitchell R; Meyer C; Omairi S; Kilic T; Paolini A; Ritvos O; Pasternack A; Matsakas A; Kylies D; Wiesch JSZ; Turner JE; Wanner N; Nair V; Eichinger F; Menon R; Martin IV; Klinkhammer BM; Hoxha E; Cohen CD; Tharaux PL; Boor P; Ostendorf T; Kretzler M; Sandri M; Kretz O; Puelles VG; Patel K; Huber TB
J Clin Invest; 2021 Jun; 131(11):. PubMed ID: 34060483
[TBL] [Abstract][Full Text] [Related]
7. Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy.
Morvan F; Rondeau JM; Zou C; Minetti G; Scheufler C; Scharenberg M; Jacobi C; Brebbia P; Ritter V; Toussaint G; Koelbing C; Leber X; Schilb A; Witte F; Lehmann S; Koch E; Geisse S; Glass DJ; Lach-Trifilieff E
Proc Natl Acad Sci U S A; 2017 Nov; 114(47):12448-12453. PubMed ID: 29109273
[TBL] [Abstract][Full Text] [Related]
8. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival.
Zhou X; Wang JL; Lu J; Song Y; Kwak KS; Jiao Q; Rosenfeld R; Chen Q; Boone T; Simonet WS; Lacey DL; Goldberg AL; Han HQ
Cell; 2010 Aug; 142(4):531-43. PubMed ID: 20723755
[TBL] [Abstract][Full Text] [Related]
9. SIRT1-NOX4 signaling axis regulates cancer cachexia.
Dasgupta A; Shukla SK; Vernucci E; King RJ; Abrego J; Mulder SE; Mullen NJ; Graves G; Buettner K; Thakur R; Murthy D; Attri KS; Wang D; Chaika NV; Pacheco CG; Rai I; Engle DD; Grandgenett PM; Punsoni M; Reames BN; Teoh-Fitzgerald M; Oberley-Deegan R; Yu F; Klute KA; Hollingsworth MA; Zimmerman MC; Mehla K; Sadoshima J; Tuveson DA; Singh PK
J Exp Med; 2020 Jul; 217(7):. PubMed ID: 32441762
[TBL] [Abstract][Full Text] [Related]
10. The therapeutic potential of blocking the activin signalling pathway.
Marino FE; Risbridger G; Gold E
Cytokine Growth Factor Rev; 2013 Oct; 24(5):477-84. PubMed ID: 23787160
[TBL] [Abstract][Full Text] [Related]
11. Treating cachexia using soluble ACVR2B improves survival, alters mTOR localization, and attenuates liver and spleen responses.
Nissinen TA; Hentilä J; Penna F; Lampinen A; Lautaoja JH; Fachada V; Holopainen T; Ritvos O; Kivelä R; Hulmi JJ
J Cachexia Sarcopenia Muscle; 2018 Jun; 9(3):514-529. PubMed ID: 29722201
[TBL] [Abstract][Full Text] [Related]
12. Muscle NAD
Hulmi JJ; Penna F; Pöllänen N; Nissinen TA; Hentilä J; Euro L; Lautaoja JH; Ballarò R; Soliymani R; Baumann M; Ritvos O; Pirinen E; Lalowski M
Mol Metab; 2020 Nov; 41():101046. PubMed ID: 32599075
[TBL] [Abstract][Full Text] [Related]
13. Differential Effects of IL6 and Activin A in the Development of Cancer-Associated Cachexia.
Chen JL; Walton KL; Qian H; Colgan TD; Hagg A; Watt MJ; Harrison CA; Gregorevic P
Cancer Res; 2016 Sep; 76(18):5372-82. PubMed ID: 27328730
[TBL] [Abstract][Full Text] [Related]
14. Transforming growth factor-beta- and Activin-Smad signaling pathways are activated at distinct maturation stages of the thymopoeisis.
Rosendahl A; Speletas M; Leandersson K; Ivars F; Sideras P
Int Immunol; 2003 Dec; 15(12):1401-14. PubMed ID: 14645149
[TBL] [Abstract][Full Text] [Related]
15. Transforming Growth Factor-β Family Ligands Can Function as Antagonists by Competing for Type II Receptor Binding.
Aykul S; Martinez-Hackert E
J Biol Chem; 2016 May; 291(20):10792-804. PubMed ID: 26961869
[TBL] [Abstract][Full Text] [Related]
16. Activin A induces skeletal muscle catabolism via p38β mitogen-activated protein kinase.
Ding H; Zhang G; Sin KW; Liu Z; Lin RK; Li M; Li YP
J Cachexia Sarcopenia Muscle; 2017 Apr; 8(2):202-212. PubMed ID: 27897407
[TBL] [Abstract][Full Text] [Related]
17. Molecular pathways leading to loss of skeletal muscle mass in cancer cachexia--can findings from animal models be translated to humans?
Mueller TC; Bachmann J; Prokopchuk O; Friess H; Martignoni ME
BMC Cancer; 2016 Feb; 16():75. PubMed ID: 26856534
[TBL] [Abstract][Full Text] [Related]
18. Signaling pathways perturbing muscle mass.
Glass DJ
Curr Opin Clin Nutr Metab Care; 2010 May; 13(3):225-9. PubMed ID: 20397318
[TBL] [Abstract][Full Text] [Related]
19. Targeting the Activin Receptor Signaling to Counteract the Multi-Systemic Complications of Cancer and Its Treatments.
Hulmi JJ; Nissinen TA; Penna F; Bonetto A
Cells; 2021 Feb; 10(3):. PubMed ID: 33671024
[TBL] [Abstract][Full Text] [Related]
20. Insight into Molecular Mechanism for Activin A-Induced Bone Morphogenetic Protein Signaling.
Xie C; Jiang W; Lacroix JJ; Luo Y; Hao J
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
